Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Alessandro Lagana, Santiago Thibaud, David T. Melnekoff, Paula Restrepo, Violetta Leshchenko, Jonathan McCafferty, Scott Newman, Abbi Kern, David Corrigan, Feras Hantash, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Shambavi Richard, Ajai Chari, Hearn J. Cho, Sundar Jagannath, Joshua Richter, Samir Parekh

Blood (2022) 140 (Supplement 1): 4388–4390.

https://doi.org/10.1182/blood-2022-166572

Published: 2022

Journal Articles

Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone

Muhammad Elnaggar, David T. Melnekoff, Sarita Agte, Christos Adamopoulos, Mark M. Stevens, Violetta Leshchenko, Katerina Kappes, Daniel Verina, Poulikos I. Poulikakos, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 4720.

https://doi.org/10.1182/blood-2021-151512

Published: 2021

Journal Articles

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, Violetta Leshchenko, Sarita Agte, Yogita Ghodke-Puranik, Joy Jiang, Mark M. Stevens, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Lagana, Samir Parekh

Blood (2021) 138 (Supplement 1): 457.

https://doi.org/10.1182/blood-2021-150522

Published: 2021

Journal Articles

Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

Donna R Edwards, MPH, PhD, Pei-yu Kuo, MS, Alessandro Lagana, PhD, Seongjee Park, Pavithra Nedumaran, MS, Violetta Leshchenko, PhD, Stephanie Christie, PhD, Shashidhar Jatiani, PhD, Julie Teruya-Feldstein, MD, Samir Parekh, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-143038

Published: 2020

Journal Articles

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Rafail Nikolaos Tasakis, MSc, BSc, Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Jonathan J Keats, PhD, Daniel Auclair, Deepu Madduri, MD, Joshua Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, F. Nina Papavasiliou, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3092.

https://doi.org/10.1182/blood-2019-130669

Published: 2019

Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3101.

https://doi.org/10.1182/blood-2019-130753

Published: 2019

Journal Articles

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Alessandro Lagana, PhD, Seongjee Park, Donna Edwards, Violetta Leshchenko, PhD, Marsha Crochiere, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Joshua Richter, Ajai Chari, MD, Hearn Jay Cho, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2018) 132 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2018-99-116500

Published: 2018

Journal Articles

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 59.

https://doi.org/10.1182/blood-2018-99-116828

Published: 2018

Journal Articles

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

Alessandro Lagana, PhD, David Melnekoff, BS, MSc, Itai Beno, PhD, Violetta Leshchenko, PhD, Deepak Perumal, PhD, Jonathan J. Keats, PhD, Mary DeRome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 325.

https://doi.org/10.1182/blood.V130.Suppl_1.325.325

Published: 2017

Journal Articles

Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine

David Melnekoff, BS, MSc, Alessandro Lagana, PhD, Wissam Hamou, PhD, Kimaada Allette, BS, Itai Beno, PhD, Violetta Leshchenko, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Robert Sebra, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 62.

https://doi.org/10.1182/blood.V130.Suppl_1.62.62

Published: 2017

Journal Articles

Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma

Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS, MSc, Itai Beno, PhD, Deepak Perumal, PhD, Jonathan Keats, PhD, Mary DeRome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 268.

https://doi.org/10.1182/blood.V130.Suppl_1.268.268

Published: 2017

Journal Articles

MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA

Hearn Jay Cho, MD PhD, Anna Huo-Chang Mei, MS, Jami Fukui, MD, Kaity Tung, BS, Deepak Perumal, PhD, Violetta Leshchenko, PhD, Alessandro Lagana, PhD, Seunghee Kim-Schultze, PhD, Ajai Chari, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 4332.

https://doi.org/10.1182/blood.V130.Suppl_1.4332.4332

Published: 2017

Journal Articles

Inhibiting SOX11-DNA Interaction in Mantle Cell Lymphoma

Stephanie Christie, Shashidhar Jatiani, PhD, Pei-Yu Kuo, MS, Violetta Leshchenko, PhD, Abhijeet Kapoor, PhD, Paola Bisignano, PhD, Aneel Aggarwal, PhD, Marta Filizola, PhD, Samir Parekh, MD

Blood (2016) 128 (22): 1840.

https://doi.org/10.1182/blood.V128.22.1840.1840

Published: 2016

Journal Articles

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma

Matko Kalac, M.D., Ph.D., Enrica Marchi, M.D., Ph.D., Luigi Scotto, Ph.D., Jennifer Amengual, M.D., Venkatraman Seshan, Govind Bhagat, M.D., Netha Ulahannan, Violetta Leshchenko, Ph.D., Samir Parekh, M.D., Benjamin Tycko, M.D., Ph.D., Owen A. O'Connor, M.D., Ph.D.

Blood (2010) 116 (21): 435.

https://doi.org/10.1182/blood.V116.21.435.435

Published: 2010

Journal Articles

Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.

Violetta Leshchenko, PhD, Pei-Yu Kuo, MS, Rita Shaknovich, MD, PhD, Tobias Gellen, Yvonne Remache, BS, Marc Weniger, PhD, K. Stephen Suh, PhD, Andre Goy, MD, Wyndham Wilson, MD, PhD, Ira Braunschweig, MD, Amit Verma, MD, Adrian Wiestner, MD, PhD, Ari Melnick, MD, Samir Parekh, MD

Blood (2009) 114 (22): 673.

https://doi.org/10.1182/blood.V114.22.673.673

Published: 2009

NARROW

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine

Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma

MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA

Inhibiting SOX11-DNA Interaction in Mantle Cell Lymphoma

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma

Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only